Being obese may significantly increase the risk of having a fatal coronary heart disease event independent of known obesity-affiliated cardiovascular risk factors such as high blood pressure and high cholesterol, investigators in Scotland have found.
By contrast, obesity alone was not seen as significantly increasing the risk of nonfatal CHD events.
The findings, derived from the long-term follow-up of a large pharmaceutical trial, and published Feb. 15 in the journal Heart (doi:10.1136/hrt.2010.211201), suggest that fatal and nonfatal CHD events could have separate causes – and that CHD death might not be preventable by mitigating traditional cardiovascular risk factors in obese men.
“It’s assumed that nonfatal and fatal events occur along an index of severity – but maybe there’s something different going on,” Dr. Jennifer Logue of the University of Glasgow, the study’s lead investigator, said in an interview.
With the fatal events, she said, “we found an almost 60% higher risk from obesity alone.” The risk was seen after modeling for obesity-associated cardiovascular risks such as high blood pressure and high cholesterol, along with factors such as smoking, low socioeconomic status, and medications.
“If you’ve got a middle-aged man in front of you with a [body mass index] of 35 – and that’s not an uncommon sight nowadays – yes, you can treat his blood pressure and cholesterol and help him stop smoking,” Dr. Logue said. “But his weight itself is still making him at significant risk.”
Dr. Logue and colleagues examined data from 6,082 men, with a mean age of 55, who had moderate hypercholesterolemia but who were without a history of diabetes or cardiovascular disease. The men had originally been enrolled in a manufacturer-sponsored, 5-year, randomized, placebo-controlled controlled trial to determine the effectiveness of the statin drug pravastatin in preventing cardiovascular events (N. Engl. J. Med. 1995; 333:1301-7), and the follow-up period ran to 15 years.
The pravastatin trial and the first 5 years of follow-up were funded by the drug’s manufacturer, Bristol Myers Squibb and Sankyo. The final years of follow-up and Dr. Logue and colleagues’ analysis were funded by the Scottish government and a grant from Scotland’s Chest, Heart and Stroke Association, respectively. Dr. Logue and colleagues declared no conflicts of interest.
The researchers excluded from their analysis men who had had a fatal or nonfatal CHD event in the first 2 years of the study, or those who had diabetes. A total of 1,027 nonfatal and 214 fatal CHD events were included in the analysis.
Dr. Logue and colleagues created two models in an attempt to isolate the role played by obesity alone in the fatal and nonfatal CHD events. One adjusted for age, sex, and statin treatment only. The other adjusted for these factors plus known cardiovascular risk factors, including blood pressure, elevated cholesterol, smoking status, high blood pressure, and use of a host of medications affecting blood pressure or the cardiovascular system. A standard social deprivation score, a measure of socioeconomic status, was also incorporated into the model.
The risk of fatal CHD events, the investigators found, was significantly increased in men with a body mass index of between 30 and 39.9 kg/m2 in both the minimally adjusted model (HR 1.75) and the adjusted model (HR 1.60). Nonfatal CHD was not seen as independently increased by high BMI.
“This link was not seen for non-fatal CHD events and therefore, owing to large relative numbers of such events, also not seen for composite CHD events,” the investigators wrote in their analysis. “In other words, our data suggest that obesity may give greater risk for fatal CHD events than nonfatal events, even after accounting for classical CHD risk factors.”
The investigators cautioned that their results were not conclusive, but “should be considered hypothesis generating.”
Among the weaknesses of their study, they wrote, was the fact that it evaluated only men, and that the percentage of participants who were obese was relatively small, limiting its statistical power.
Among the study’s strengths, they wrote, was “the large cohort with a high number of events; this has allowed significant results to be generated while still allowing participants with events in the first 2 years to be excluded, along with those with known diabetes.” A further strength, they wrote, was having details of each death thanks to standardized government records. “Had we combined fatal and nonfatal CHD events we would have missed this important association.”
Dr. Logue and colleagues cited in their analysis a study highlighting inflammation as a possible culprit in fatal CHD events (PLoS Med. 2009 Aug. 6;6: e1000099) and another exploring the effects of adiposity on inflammation (J. Clin. Endocrinol. Metab. 2010;95:93-9).